Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methyl grevillate
- Development stage
- Preclinical
- Lead developer
- Kenya Medical Research Institute
- Modality
- Small Molecules
01
Overview
Methyl grevillate (MetG) is a nature-identical synthetic cinnamic acid derivative that acts as a selective inhibitor of *Plasmodium falciparum* histone deacetylase 1 (PfHDAC1). Originally identified through virtual screening of natural compound libraries, methyl grevillate exhibits stereospecific, multi-stage antimalarial activity against both asexual and sexual (gametocyte) erythrocytic stages, as well as the pathogenic liver stage of the malaria parasite. Preclinical evaluations demonstrate potent in vitro and in vivo efficacy against drug-sensitive and drug-resistant strains of *P. falciparum* and *P. berghei*, with negligible cytotoxicity in human cells.
- Other names
- MetGmethyl 2,5-dihydroxycinnamatemethyl-2,5-dihydroxycinnamate
Beyond the preview
Go deeper on methyl grevillate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methyl grevillate.